H.R. 2855 · 117th Congress
Star Rating for Biosimilars Act
- Stage
- In committee
- Sponsor
- Paul Tonko
- Introduced
- 2021-04-26
- Latest action
- 2021-04-27 · Referred to the Subcommittee on Health.
Summary
Star Rating for Biosimilars Act
This bill requires the Centers for Medicare & Medicaid Services (CMS) to establish quality measures regarding biosimilar biological products under the five-star performance rating system for Medicare Advantage plans. The measures must assess the level of access that plans provide to covered biosimilars, including with respect to formularies, cost-sharing, and utilization management.
The CMS must also incorporate such measures into similar rating systems for plans under the Medicare prescription drug benefit.